This is a topic fresh off the ACannabis conference from this year. Why? Two reasons: it was a fairly decent question asked during a leadership panel and also, as the industry looks to consolidate in the next 5 years, this topic is becoming more relevant. So, if you're a Chinese investor, a seasoned Australian cannabis player, or someone entirely new to the market, this one's for you.
Buying a medicinal cannabis clinic isn't like buying a café. You can't just count the chairs, check the coffee machine, and hand over a cheque. If you could, we wouldn't be writing this article. The thing is, when you buy a medicinal cannabis clinic, what you're really buying is trust compliance history, prescribing relationships, and a marketing system.
If you're circling a clinic acquisition in Australia's medicinal cannabis sector right now, you're in good company. The market has gone from a handful of niche prescribers in 2016 to a genuinely large, fast-consolidating industry, and buyers with cash are shopping. But most of the "valuations" floating around in early conversations are back-of-napkin guesses dressed up as due diligence. Let's try and fix that.
Why everyone's suddenly interested in buying medicinal cannabis clinics
Since legal access pathways opened up in 2016, the medicinal cannabis sector in Australia has expanded rapidly, with a proliferation of telehealth services built around it. Telehealth cannabis prescribing has become a genuinely large slice of the broader telehealth economy, and forecasts point to continued strong growth this decade. That growth curve is exactly why private equity, health-sector consolidators, and ambitious multi-clinic operators are circling: a fragmented market full of single-clinic operators is a textbook roll-up opportunity.
But here's the twist that makes this sector spicier than your average healthcare roll-up: it's also under a regulatory microscope. Consultation practices, prescribing volumes, and commercial ties between clinics and dispensing pharmacies have all drawn scrutiny, including a CHOICE investigation into short consultations and conflicts of interest, and enough concern from GPs and regulators that the government asked the therapeutic regulator to look into "unscrupulous and possibly unsafe behaviour" among some telehealth cannabis providers. That backdrop matters enormously for valuation, because in the medicinal cannabis industry, non-compliance can be a killer.
The three lenses every buyer should look through
Cannabis-adjacent businesses get valued with the same core toolkit used across healthcare and general M&A. You just have to apply it with cannabis-specific goggles on.
1. The income approach (aka "show me the money")
This is where most deals actually get priced. You take a normalised earnings figure (usually EBITDA, sometimes Seller's Discretionary Earnings for smaller single-operator clinics) and apply a multiple. For general healthcare-style practices, valuers commonly work from revenue or earnings multiples benchmarked against comparable transactions, then adjust up or down for size, growth, and risk factors specific to the practice being valued.
For a medicinal cannabis clinic specifically, "normalised earnings" needs some real detective work:
- Strip out one-off marketing spend spikes or discounts used to inflate patient numbers pre-sale
- Adjust for owner compensation if the founder-prescriber is also the main clinician
- Separate recurring consultation revenue from one-off or seasonal promotional revenue
2. The market approach (aka "what did the last one sell for?")
This method leans on comparable transactions or comparable public companies to derive a pricing multiple, then applies it to your target. The catch in medicinal cannabis: the sector is still relatively young and volatile, so there's a limited pool of genuinely comparable deals to draw multiples from, andcmany of the available comparables need adjusting for differences in size, profitability, and company-specific risk before they're useful.
Translation: don't trust a multiple someone quotes you from a random overseas dispensary deal. Cannabis retail and cannabis clinical prescribing are different animals entirely, and Australian regulation is its own beast again.
3. The asset approach (aka "what's actually on the shelf?")
Least useful for a going-concern clinic, but worth a glance for the tail-end scenario: what would the licences, equipment, EMR/patient management system, and domain/brand assets fetch if the clinic closed tomorrow? This sets your valuation floor, not your ceiling.
Most credible valuers blend all three, weighting income and market approaches most heavily for a clinic with real, provable cash flow.
What actually moves the multiple in a cannabis clinic deal
This is the part generic M&A guides skip, and it's where clinic-specific value really lives or dies.
Patient volume, retention, and the reorder rate. A clinic with 3,000 patients on a 90-day repeat script cycle is worth dramatically more than a clinic with 3,000 patients who churned after one consult. Ask for cohort retention data, not just headline patient counts.
Prescriber depth, not prescriber dependence. If 80% of scripts run through one Authorised Prescriber who might walk after settlement, that's a massive key-person risk that should hammer the multiple. Buyers want a roster of AHPRA-registered clinicians, not a cult of personality.
Regulatory and compliance posture. Given the current scrutiny on consultation length, product-linked incentives, and dispensing conflicts of interest, a clinic that can prove clean, well-documented consultations and clear separation from any dispensing pharmacy is worth a real premium over one that can't. This is the single fastest way a clinic's "value" evaporates mid-negotiation: a buyer's lawyers find a commercial arrangement that looks like it's incentivising prescribing volume over patient need, and the multiple gets slashed on the spot.
Where new patients actually come from. This is the one sellers most often get wrong when they pitch their own business. A clinic that's 90% dependent on paid Google and Meta ads is buying every single patient, forever, with no asset being built. A clinic with strong organic search visibility, referral partnerships, and content that ranks, the kind of durable growth engine a specialist medicinal cannabis marketing agency builds over time, is compounding an asset that keeps paying off after the acquisition closes. Buyers increasingly ask sellers to break down patient acquisition cost by channel for exactly this reason, and a clinic that's outsourced its growth to a genuinely capable medicinal cannabis marketing agency, one that understands the advertising restrictions unique to prescription medicines in Australia, tends to show a healthier, more defensible acquisition funnel than one running ad-hoc paid campaigns in-house.
Systems, not spreadsheets. Does the clinic run on a proper EMR with audit trails, or a shared spreadsheet and a group chat? Buyers pay more for operations they can plug straight into an existing platform.
Product and pathway diversity. Clinics leaning on the SAS-B pathway for a narrow product range carry more supply and regulatory concentration risk than clinics with broader Authorised Prescriber approvals across multiple conditions and formulations.
A (very) rough worked example
Say a target clinic has:
- Normalised EBITDA of $600,000
- Diversified prescriber base, clean compliance record, no dispensing conflicts
- 60% of new patients arriving organically, thanks to two years of solid SEO and content work rather than pure paid acquisition
- A modern EMR and documented consultation processes
A buyer might comfortably apply a multiple toward the higher end of the healthcare-services range for this sub-sector, reflecting low key-person risk and a durable growth channel, landing somewhere in the vicinity of $2.4–3.6 million, before working capital and licence-transfer adjustments.
Flip the profile: single prescriber, thin compliance documentation, 90% paid-ad dependence, revenue concentrated in one high-margin product line under regulatory review. Same $600,000 EBITDA. Much lower multiple, because a buyer is really just purchasing one year of fragile cash flow, not a compounding business.
Red flags that should pause any term sheet
- Consultation times that look rushed relative to what's clinically appropriate for the conditions being treated
- Commercial arrangements or incentives tied to a particular dispensing pharmacy or product brand
- No clear separation of duties between the prescribing clinician and any product-supply relationship
- Patient records that can't demonstrate genuine clinical assessment and follow-up
- A single founder-prescriber who is, functionally, the entire business
Any one of these can trigger a valuation discount well beyond what a spreadsheet multiple would suggest, because they represent regulatory exposure the buyer inherits on day one.
The bottom line
Valuing a medicinal cannabis clinic for acquisition means blending the standard M&A toolkit (income, market, and asset approaches) with a genuinely sector-specific risk lens: prescriber concentration, compliance posture, and how sustainably the clinic actually finds its patients. The clinics that command premium multiples aren't necessarily the ones with the biggest top-line revenue; they're the ones that have built something durable: clean compliance, diversified prescribing, and a growth engine (often built in partnership with a specialist medicinal cannabis marketing agency) that doesn't disappear the moment the ad budget gets reviewed post-acquisition.
If you're on either side of a deal like this, get a proper valuation done before you fall in love with a number someone put in a pitch deck. The multiple always tells the truth, even when the seller's slide deck doesn't.
